治疗|阿贝西利多少钱一盒？阿贝西利治疗乳腺癌效果怎样？( 二 ) 阿贝西利|内分泌|中国|Centre|患

文章图片

在Medicine Centre上买药的步骤比较简单，和平常网购差别不大。首先打开Medicine Centre药房官方网站（自行百度），在首页的右上方可以选择多种语言，比如切换到中文。通过分类功能或者搜索功能找到对应药品（阿贝西利），完成下单并付款。付款后将付款凭证上传到订单页面。或者将订单编号和付款凭证一起发送给客服经理。

文章图片

一般在线下单后他们会在几天内给你分装并打包好，然后用国际EMS将药物寄到国内，整个过程一般在十多天左右。纸质发票会随国际快递一起邮寄，如果需要电子发票则需要联系客服经理索取。
阿贝西利的上市为国内HR+/HER2-晚期乳腺癌患者带来了更多治疗选择，阿贝西利在内分泌耐药、内脏转移人群中表现出的治疗优势让我们充满期盼，并且在monarchE研究中针对早期高危患者也展示出初步优势。因此，我们希望通过阿贝西利的加入，让更多早期高危或晚期HR+/HER2-乳腺癌患者有了更多的选择，能够有生活质量地延长生存。
参考文献：
[1]Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020 Feb 6;382(6):514-524.
[2]Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 Jul 25;381(4):307-316.
[3] Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019 Sep 29;6(1):116–24.
[4]Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018 Nov 15;379(20):1926-1936.
[5] Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019 Apr;174(3):719-729.
[6] Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib Combined with Endocrine
Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High Risk,Early Breast Cancer (monarchE). 2020 ESMO. LBA5.
[7] Mayer EL, Gnant MI, DeMichele A, et al. PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer. 2020 ESMO. LBA12.
[8] Loibl S, Marme F, Martin M, et al. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B. 2020 SABCS. GS1-02.
[9]Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224.
[10] Delach S, Caponigro G. Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6. 2020 SABCS. PS19-10.
[11] Thibault S, Hu W, Hirakawa B, et al. Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology. Mol Cancer Ther. 2019 Feb;18(2):257-266.
[12] Jiang ZF, Hu XC, Zhang QY, et al. Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study. 2020 SABCS. PS13-25.